Press Releases


February 20, 2018
Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene

February 13, 2018
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics & Biosimilars Congress Europe (March 2018)


June 14, 2017
Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV001 a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN® half-life extension technology

March 13, 2017
Distinguished Cancer Physician-Scientist Dr. Herbert (Bob) Pinedo joins Amunix Scientific Advisory Board

February 15, 2017
Amunix announces broad alliance with Genentech using XTEN® technology

February 13, 2017
Amunix Appoints Fred Hausheer, MD, FACP, as Chief Medical Officer

January 5, 2017
Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix’ XTEN® half-life extension technology


December 19, 2016
IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases

September 29 2016
Phase 3 enrollment initiated in Japan for Versartis’ long-acting growth hormone based on Amunix’ XTEN® technology

September 1, 2016
Long acting growth hormone based on Amunix’ XTEN® technology completes enrollment of Phase 3 trial

August 22, 2016
Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD

March 3, 2016
Harold E. “Barry” Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors


November 16, 2015
Amunix Establishes GMP Manufacturing of XTEN® at UN-L BPDF

October 26, 2015
Amunix, Inc. Announces Extension of Evaluation Agreement with Roche (RHHBY)

September 18, 2015
Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Growth-Hormone-XTEN (VRS-317, Somavaratan) in Children.

January 5, 2015
Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN® Products


December 17, 2014
Amunix Announces Option Exercise by Eli Lilly and Company for XTEN® Product for People with Diabetes

October 28, 2014
Amunix and PolyPeptide Enter Into Partnership to Produce XTEN® Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics

October 27, 2014
Amunix Signs a Services and Supply Agreement With the University of Nebraska-Lincoln to Produce GMP-Grade XTEN® for Pharmaceutical Therapeutics

July 23, 2014
Amunix and PolyPeptide Publish Multivalent Antiviral XTEN®-Peptide Conjugates in vivo Studies in American Chemical Society’s Journal “Bioconjugate Chemistry”

June 30, 2014
Amunix Congratulates Versartis on its Positive Phase 2a Results with VRS-317

June 5, 2014
Amunix Presents XTEN® Half-life Extension Technology at Next Generation Protein Therapeutics Summit

May 28, 2014
Amunix to Present Unpublished Data at Next Generation Protein Therapeutics Summit

April 21, 2014
Biogen Idec Signs License Agreement with Amunix for XTENylated Factor VIII

January 7, 2014
Amunix Announces Expansion to Licensing Agreement with Janssen for Its Proprietary XTEN® Technology


August 14, 2013
Amunix Announces Update to Licensing Agreement with Janssen for Its Proprietary XTEN Technology

July 1, 2013
Preclinical Data from Biogen Idec-Amunix Partnership Presented at ISTH Congress

January 21, 2013
Amunix Announces Licensing Agreement for its Proprietary XTEN Technology


April 13, 2011
Amunix Signs Research Collaboration with Biogen Idec for Next Generation Long-Lasting Blood Factor Products


November 15, 2009
XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics